TD Cowen Initiates Coverage On Alamar Biosciences with Buy Rating, Announces Price Target of $30

Benzinga Newsdesk www.benzinga.com Neutral 51.5%

Neg 0% Neu 51.5% Pos 0%

TD Cowen analyst Dan Brennan initiates coverage on Alamar Biosciences (NASDAQ:ALMR) with a Buy rating and announces Price Target of $30.